In regulatory news:

A new report from the National Academies of Sciences, Engineering and Medicine encourages the FDA to review the pros and cons of opioids, including social effects. The move follows the FDA’s decision to request that the maker of Opana ER remove its drug from the market, saying that the risks of the long-acting painkiller (including addiction) outweigh its benefits. The report also recommends better access to treatment for opioid addiction like buprenorphine; year-round drug takeback programs at pharmacies; and encourages insurers to pay for more nontraditional pain therapy like cognitive behavioral therapy.

Read more via Claims Journal here. Download the report here.

Leave a Comment

Your email address will not be published. Required fields are marked *